Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 452

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 452
---
 |             |     |      |     |        15,528 |
| Amortization of intangibles                |     |           714 |     |        -714 |     | 5(c) |     |             — |
| Total operating expenses                   |     |        27,520 |     |        -714 |     |      |     |        26,806 |
| Operating loss                             |     |       -26,644 |     |         714 |     |      |     |       -25,930 |
| Other income (expense), net:               |     |               |     |             |     |      |     |               |
| Interest income                            |     |             — |     |             |     |      |     |             — |
| Interest expense                           |     |        -1,878 |     |        -550 |     | 5(d) |     |        -2,428 |
| Other income (expense)                     |     |             2 |     |             |     |      |     |             2 |
| Total other (expense) income               |     |        -1,876 |     |        -550 |     |      |     |        -2,426 |
| Net loss before provision for income taxes |     |       -28,520 |     |         164 |     |      |     |       -28,356 |
| Provision for income taxes                 |     |           290 |     |             |     |      |     |           290 |
| Net loss                                   |     |     $(28,230) |     |        $164 |     |      |     |     $(28,066) |

5(c) Reflects the elimination of amortization expense related to the IP which was transferred to Ligand through the IP Assignment. 5(d) Reflects the interest expense associated with the Ligand Bridge Loan and PIPE Investor Bridge Loans executed in March and April 2025, respectively, at a rate of 4.36%, which reflects the three month U.S. treasury rate as of May 23, 2025.

262

#### TABLE OF CONTENTS

### DESCRIPTION OF SECURITIES

#### General
The following description of Channel’s securities is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our articles of incorporation, and our bylaws, each of which are filed as an exhibit to Channel’s Annual Report